University of Groningen
Radiopharmaceuticals for translational imaging studies in the field of cancer immunotherapy
van der Veen, Elly
DOI:
10.33612/diss.128579303
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van der Veen, E. (2020). Radiopharmaceuticals for translational imaging studies in the field of cancer
immunotherapy. University of Groningen. https://doi.org/10.33612/diss.128579303
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Radiopharmaceuticals for
translational imaging studies
in the field of cancer immunotherapy
van der Veen, Elly L.
Radiopharmaceuticals for translational imaging studies in the field of cancer immunotherapy
Thesis, University of Groningen, Groningen, The Netherlands ISBN (printed version): 978-94-034-2762-1
ISBN (electronic version): 978-94-034-2763-8 © 2020 - Elly L. van der Veen
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronically, mechanically, by photo-copying, recording or otherwise, without the prior permission of the author.
Cover design and layout: © evelienjagtman.com Printed by: Ridderprint | www.ridderprint.nl
Printing of this thesis was financially supported by UMCG Graduate School of Medical Sciences, Stichting Werkgroep Interne Oncologie and the University of Groningen.
Radiopharmaceuticals for
translational imaging studies
in the field of cancer immunotherapy
Proefschrift
ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op woensdag 8 juli 2020 om 14.30 uur
door
Elly Lieke van der Veen geboren op 27 januari 1989
Promotores
Prof. dr. E.G.E. de Vries Dr. M.N. Lub-de Hooge Beoordelingscommissie Prof. dr. N.H. Hendrikse Prof. dr. E. Vellenga Prof. dr. R.A.J.O. Dierckx
Paranimfen Francien Talens Suzanne Jansen
CONTENTS
Chapter 1 General introduction and outline of thesis 9 Chapter 2 Molecular imaging to enlighten cancer immunotherapies and
underlying involved processes
17
Cancer Treat Rev. 2018;70:232-244.
Chapter 3 89Zr-pembrolizumab biodistribution is influenced by PD-1 mediated
uptake in lymphoid organs
69
Manuscript submitted
Chapter 4 Molecular imaging of PD-L1 expression and dynamics with the adnectin-based PET tracer 18F-BMS-986192
111
J Nucl Med. 2020; Epub ahead of print.
Chapter 5 Clinical-grade N-(4-[18F]fluorobenzoyl)-interleukin-2 for PET
imaging of activated T-cells in humans
133
EJNMMI Radiopharm Chem. 2019;4:15.
Chapter 6 Development and evaluation of interleukin-2 derived radiotracers for PET imaging of T-cells in mice
203
J Nucl Med. 2020; Epub ahead of print.
Chapter 7 89Zr-atezolizumab imaging as a non-invasive approach to assess
clinical response to PD-L1 blockade in cancer
229
Nat Med. 2018;24:1852-1858.
Chapter 8 Summary, general discussion and future perspectives 269 Chapter 9 Nederlandse samenvatting (Dutch summary) 281
Appendices About the author 290
List of publications 291
